Showing 1 - 11 results of 11 for search 'Julie Delyon', query time: 0.39s
Refine Results
-
1
Endemic Kaposi’s Sarcoma by Perla El Zeinaty, Céleste Lebbé, Julie Delyon
Published 2023-01-01
Article -
2
Atypical <i>BRAF</i> and <i>NRAS</i> Mutations in Mucosal Melanoma by Nicolas Dumaz, Fanélie Jouenne, Julie Delyon, Samia Mourah, Armand Bensussan, Céleste Lebbé
Published 2019-08-01
Article -
3
-
4
18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors by Alexia Rivas, Julie Delyon, Antoine Martineau, Estelle Blanc, Clara Allayous, Laetitia Da Meda, Pascal Merlet, Céleste Lebbé, Barouyr Baroudjian, Laetitia Vercellino
Published 2022-06-01
Article -
5
FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma by Pauline Tétu, Julie Delyon, Jocelyne André, Coralie Reger de Moura, Malak Sabbah, Ghanem E Ghanem, Maxime Battistella, Samia Mourah, Céleste Lebbé, Nicolas Dumaz
Published 2020-04-01
Article -
6
TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro by Julie Delyon, Anaïs Vallet, Mélanie Bernard-Cacciarella, Isabelle Kuzniak, Coralie Reger de Moura, Baptiste Louveau, Fanélie Jouenne, Samia Mourah, Céleste Lebbé, Nicolas Dumaz
Published 2023-05-01
Article -
7
Systemic Treatment Initiation in Classical and Endemic Kaposi’s Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study by Lina Benajiba, Jérôme Lambert, Roberta La Selva, Delphine Cochereau, Barouyr Baroudjian, Jennifer Roux, Jérôme Le Goff, Cécile Pages, Maxime Battistella, Julie Delyon, Céleste Lebbé
Published 2021-05-01
Article -
8
Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases by Pauline Tétu, Lila Sirven-Villaros, Stefania Cuzzubbo, Renata Ursu, Barouyr Baroudjian, Julie Delyon, François Nataf, Constance De Margerie-Mellon, Clara Allayous, Wendy Lefevre, Antoine F. Carpentier, Céleste Lebbé
Published 2020-09-01
Article -
9
Baseline Genomic Features in <i>BRAFV600</i>-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care by Baptiste Louveau, Fanelie Jouenne, Coralie Reger de Moura, Aurelie Sadoux, Barouyr Baroudjian, Julie Delyon, Florian Herms, Adele De Masson, Laetitia Da Meda, Maxime Battistella, Nicolas Dumaz, Celeste Lebbe, Samia Mourah
Published 2019-08-01
Article -
10
Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans by Jessica Beaziz, Maxime Battistella, Julie Delyon, Cécile Farges, Oren Marco, Cécile Pages, Christine Le Maignan, Laetitia Da Meda, Nicole Basset-Seguin, Matthieu Resche-Rigon, Anouk Walter Petrich, Delphine Kérob, Céleste Lebbé, Barouyr Baroudjian
Published 2021-05-01
Article -
11
Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study by Sandra Huynh, Laurent Mortier, Caroline Dutriaux, Eve Maubec, Marie Boileau, Olivier Dereure, Marie-Therese Leccia, Jean-Philippe Arnault, Florence Brunet-Possenti, Francois Aubin, Brigitte Dreno, Marie Beylot-Barry, Celeste Lebbe, Wendy Lefevre, Julie Delyon
Published 2020-06-01
Article